JP2023542065A5 - - Google Patents

Info

Publication number
JP2023542065A5
JP2023542065A5 JP2022580314A JP2022580314A JP2023542065A5 JP 2023542065 A5 JP2023542065 A5 JP 2023542065A5 JP 2022580314 A JP2022580314 A JP 2022580314A JP 2022580314 A JP2022580314 A JP 2022580314A JP 2023542065 A5 JP2023542065 A5 JP 2023542065A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
cancer
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022580314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542065A (ja
JP7794766B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/055547 external-priority patent/WO2021260578A1/en
Publication of JP2023542065A publication Critical patent/JP2023542065A/ja
Publication of JP2023542065A5 publication Critical patent/JP2023542065A5/ja
Priority to JP2025264238A priority Critical patent/JP2026048890A/ja
Application granted granted Critical
Publication of JP7794766B2 publication Critical patent/JP7794766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022580314A 2020-06-24 2021-06-23 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ Active JP7794766B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025264238A JP2026048890A (ja) 2020-06-24 2025-12-18 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043528P 2020-06-24 2020-06-24
US63/043,528 2020-06-24
PCT/IB2021/055547 WO2021260578A1 (en) 2020-06-24 2021-06-23 Combination of antibody-drug conjugate and cdk9 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025264238A Division JP2026048890A (ja) 2020-06-24 2025-12-18 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ

Publications (3)

Publication Number Publication Date
JP2023542065A JP2023542065A (ja) 2023-10-05
JP2023542065A5 true JP2023542065A5 (https=) 2024-06-24
JP7794766B2 JP7794766B2 (ja) 2026-01-06

Family

ID=76971937

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580314A Active JP7794766B2 (ja) 2020-06-24 2021-06-23 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ
JP2025264238A Pending JP2026048890A (ja) 2020-06-24 2025-12-18 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025264238A Pending JP2026048890A (ja) 2020-06-24 2025-12-18 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ

Country Status (6)

Country Link
US (1) US20230233540A1 (https=)
EP (1) EP4171654A1 (https=)
JP (2) JP7794766B2 (https=)
CN (1) CN116615248A (https=)
TW (1) TW202216207A (https=)
WO (1) WO2021260578A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4514391A1 (en) * 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
WO2025054996A1 (en) * 2023-09-15 2025-03-20 Duality Biologics (Suzhou) Co., Ltd. Antibody-drug conjugate
WO2025162211A1 (zh) * 2024-01-29 2025-08-07 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物治疗胃癌的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
WO2007133855A2 (en) 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
IN2014DN06806A (https=) 2012-02-10 2015-05-22 Univ Maryland
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
AU2014371934B2 (en) 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
IL310627B2 (en) 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
ES2728356T3 (es) * 2015-06-29 2019-10-23 Astrazeneca Ab Derivados de amidas policíclicas como inhibidores de CDK9
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
IL324591A (en) 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved antibody-drug conjugate production methods
US20210101881A1 (en) * 2018-02-12 2021-04-08 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Pyrimidine compound, preparation method thereof and medical use thereof

Similar Documents

Publication Publication Date Title
JP2023539715A5 (https=)
JP2023542066A5 (https=)
JP2023545096A5 (https=)
JP2023542065A5 (https=)
JPWO2020122034A5 (https=)
JP2025041725A5 (https=)
JP2023510905A5 (https=)
JP2023515235A5 (https=)
JPWO2020130125A5 (https=)
JP2022515198A5 (https=)
JP2020007311A5 (https=)
JP2020517616A5 (https=)
JP2023070678A5 (https=)
JP2017095457A5 (https=)
FI4212552T3 (fi) Anti-her2-vasta-aine-lääkeainekonjugaatti
JP2017186337A5 (https=)
RU2016130986A (ru) Ингибитор киназы и его применение
JP2017506234A5 (https=)
ME02928B (me) Dll3 modulatori i metode upotrebe
JP2024533356A5 (https=)
JP2022540890A5 (https=)
JP2021514395A5 (https=)
JP2024543508A5 (https=)
JP2023519261A5 (https=)
JP2024532845A5 (https=)